Zura Bio Limited Class A Ordinary Shares (ZURA)
Stock · NASDAQ · Health Care
$5.72as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$5.58
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About ZURA
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 40
- Website
- zurabio.com/
Fundamentals
- 1-day range
- $5.49$5.85
- Market cap
- $524.39M
- P/E (trailing)
- —
- P/E (forward)
- -9.81
- EPS (trailing)
- $-0.75
- Dividend yield
- —
- Beta
- -0.06
- Avg. volume
- 1.28M
52-week range
$1.88$7.44
Next earnings: November 12, 2026 · EPS estimate $-0.20confirmed
Forecasts
6 analyst ratings
Buy 93%
Hold 7%
Sell 0%
1-year price forecast
High
$26
+354.5%
Median
$18
+214.7%
Low
$11
+92.3%
Zura Bio Limited Class A Ordinary Shares Competitors
Chosen by industry and closest market cap.
- ZURAZura Bio Limited Class A Ordinary Shares$5.73▼ 2.05%Market cap $524.39MP/E —$1.88$7.44
- TECXTectonic Therapeutic Inc. Common Stock$35.69▼ 2.75%Market cap $526.83MP/E —$14.39$39.53
- FDMT4D Molecular Therapeutics Inc. Common Stock$14.65▼ 1.74%Market cap $527.47MP/E —$5.97$16.93
- PRMEPrime Medicine Inc. Common Stock$3.62▼ 0.69%Market cap $507.54MP/E —$2.67$6.94
- DNAGinkgo Bioworks Holdings Inc. Class A Common Stock$6.98▼ 3.93%Market cap $555.49MP/E —$5.37$17.58
- VALNValneva SE American Depositary Shares$6.43▼ 2.13%Market cap $491.51MP/E —$2.03$5.34
- PROKProKidney Corp. Class A Ordinary Shares$1.84▲ 1.10%Market cap $471.21MP/E —$1.3$3.48
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ZURA Zura Bio Limited Class A Ordinary Shares | $524.39M | — | $5.73 | ▼ 2.05% | $1.88$7.44 |
| TECX Tectonic Therapeutic Inc. Common Stock | $526.83M | — | $35.69 | ▼ 2.75% | $14.39$39.53 |
| FDMT 4D Molecular Therapeutics Inc. Common Stock | $527.47M | — | $14.65 | ▼ 1.74% | $5.97$16.93 |
| PRME Prime Medicine Inc. Common Stock | $507.54M | — | $3.62 | ▼ 0.69% | $2.67$6.94 |
| DNA Ginkgo Bioworks Holdings Inc. Class A Common Stock | $555.49M | — | $6.98 | ▼ 3.93% | $5.37$17.58 |
| VALN Valneva SE American Depositary Shares | $491.51M | — | $6.43 | ▼ 2.13% | $2.03$5.34 |
| PROK ProKidney Corp. Class A Ordinary Shares | $471.21M | — | $1.84 | ▲ 1.10% | $1.3$3.48 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22benzinga · 8/12/2026
- Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22Benzinga · 8/12/2026
- Guggenheim Maintains Buy on Zura Bio, Raises Price Target to $20Benzinga · 8/12/2026
- Zura Bio Q2 EPS $(0.21) Misses $(0.20) EstimateBenzinga · 8/11/2026
Insider Activity
Insider Actions →Acquired
2.62M
Disposed
0
- Nirula Ajay · June 17, 2026 · Grant51.0K
- Thiara Parvinder · June 17, 2026 · Grant51.0K
- Schoch Steven J · June 17, 2026 · Grant51.0K
- Mark Eisner · June 17, 2026 · Grant51.0K
- Becker Daniel J. · June 17, 2026 · Grant51.0K
- Jennifer Jarrett · June 17, 2026 · Grant51.0K
- Amit Munshi · June 17, 2026 · Grant51.0K
- Nistala Kiran · April 1, 2026 · Grant340.9K
- Eric J. Hyllengren · April 1, 2026 · Grant340.9K
- Whale Gary · April 1, 2026 · Grant263.0K
- Kim Davis · April 1, 2026 · Grant425.7K
- Kulkarni Sandeep Chidambar · April 1, 2026 · Grant894.0K
See the full, filterable feed with live charts on the MarketWall dashboard.